Market Overview

Regeneron Shares Fall Following BMO's Note Of Roche Preference

Share:
Related REGN
Regeneron Is 'One Of The Stronger Growers In Biotech'
Regeneron CEO And CFO Met With Citi: Here Are The Takeaways
Lilly, J&J, Novo Battle Diabetes -- And Each Other (Investor's Business Daily)

Shares of Regeneron Pharmaceuticals (NASDAQ: REGN) are down three percent following BMO analyst Jim Birchenough's note of customers cost preference of Roche's Avastin.

Birchenough remarked that there has been “broad reconsideration” of use of “low-cost” Avastin over Regeneron's Eylea by patients. The analyst noted that roughly 10 percent of Eylea patients at an investigator's clinic are being switched back to Avastin.

BMO reported that there has been increased inquiry into brand anti-VEGF therapy over Avastin, with “brand therapy becoming harder to justify for stable patients with lower visual acuity.”

Shares of Regeneron closed at $297.69 on Thursday. The stock fell as much as 5.1 percent to $282.52 in Friday's morning trading.

Latest Ratings for REGN

DateFirmActionFromTo
Jun 2016BernsteinInitiates Coverage onOutperform
Apr 2016Wells FargoDowngradesOutperformMarket Perform
Apr 2016Leerink SwannMaintainsOutperform

View More Analyst Ratings for REGN
View the Latest Analyst Ratings

Posted-In: BMO Jim BirchenoughAnalyst Color Short Ideas Analyst Ratings Trading Ideas

 

Related Articles (REGN)

View Comments and Join the Discussion!